• Users Online: 236
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 8  |  Issue : 1  |  Page : 13-19

Safety and efficacy of oxycodone in cancer patients with moderate-to-severe cancer pain: A single-medical center experiences


Division of Colorectal Surgery, Department of Surgery, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Kaohsiung, Taiwan

Correspondence Address:
Dr. Hong- Hwa Chen
Division of Colorectal Surgery, Department of Surgery, Chang Gung Memorial Hospital - Kaohsiung Medical Center, No. 123, Dayi Road, Niaosong District, Kaohsiung 833
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCRP.JCRP_15_20

Rights and Permissions

Background: The study aimed at evaluating the safety and tolerability of oxycodone in patients with moderate-to-severe cancer pain at a medical center in southern Taiwan. Materials and Methods: This was a subgroup analysis of a 12-week, uncontrolled, open-label, multicentric study. During the treatment phase, all participants received control-released (CR) oxycodone and/or immediate-released (IR) oxycodone. The primary end point was the number and percentage of patients with adverse events (AEs) and serious adverse events (SAEs). The secondary end points included patient-reported outcomes and titration of oxycodone. Results: A total of 19 patients were enrolled at this medical center. A total of 56 AEs were documented in 12/19 (63.2%) patients, of which, only 4/56 (7.1%) AEs were treatment-related adverse events occurring in 3/19 (15.8%) patients and no treatment-related SAEs were observed. Most AEs were mild and typical for opioids administered to patients with cancer pain. The most AEs involved the gastrointestinal systems (23%), such as nausea, constipation, and vomiting. At the study end, pain intensity of Numeric Rating Scale score had significantly decreased from 6.3 to 1.6 points; the quality of life on the European Quality of Life Visual Analog Scale (EQ-VAS) median score had improved from 50 to 60 points; and proportion of good/excellent? quality of analgesia (QoA) had increased from 5.3% to 100%. The interesting findings of EQ5D item analyses that the top two improvements were anxiety/depression and pain/discomfort, whereas “mobility” and “self-care” became worse, demonstrated that improvement in cancer pain seems to have more improvement on patients' anxiety/depression.” The median stable dose was 20 mg/day and the median time to reach stable dose was 1 day. Conclusion: CR and IR oxycodone are tolerable and effective in managing moderate-to-severe cancer pain among patients with colorectal cancers s at this medical center. Neither new safety signals nor significant bowel function disorders were noted. Together with the high acceptability and improvements on anxiety/depression and pain/discomfort on Taiwanese cancer patients, CR and IR oxycodone can be another valuable pain management option used for the daily control of moderate-to-severe cancer pain.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed703    
    Printed16    
    Emailed0    
    PDF Downloaded73    
    Comments [Add]    

Recommend this journal